Abstract
Acquired hearing loss is the predominant neurodegenerative condition associated with aging in humans. Although mutations on several genes are known to cause congenital deafness in newborns, few genes have been implicated in age-related hearing loss (ARHL), perhaps because its cause is likely polygenic. Here, we generated mice lacking lysosomal calcium channel mucolipins 3 and 1 and discovered that both male and female mice suffered a polygenic form of hearing loss. Whereas mucolipin 1 is ubiquitously expressed in all cells, mucolipin 3 is expressed in a small subset of cochlear cells, hair cells (HCs) and marginal cells of the stria vascularis, and very few other cell types. Mice lacking both mucolipins 3 and 1, but not either one alone, experienced hearing loss as early as at 1 month of age. The severity of hearing impairment progressed from high to low frequencies and increased with age. Early onset of ARHL in these mice was accompanied by outer HC (OHC) loss. Adult mice conditionally lacking mucolipins in HCs exhibited comparable auditory phenotypes, thereby revealing that the reason for OHC loss is mucolipin codeficiency in the HCs and not in the stria vascularis. Furthermore, we observed that OHCs lacking mucolipins contained abnormally enlarged lysosomes aggregated at the apical region of the cell, whereas other organelles appeared normal. We also demonstrated that these aberrant lysosomes in OHCs lost their membrane integrity through lysosomal membrane permeabilization, a known cause of cellular toxicity that explains why and how OHCs die, leading to premature ARHL.
SIGNIFICANCE STATEMENT Presbycusis, or age-related hearing loss (ARHL), is a common characteristic of aging in mammals. Although many genes have been identified to cause deafness from birth in both humans and mice, only a few are known to associate with progressive ARHL, the most prevalent form of deafness. We have found that mice lacking two lysosomal channels, mucolipins 3 and 1, suffer accelerated ARHL due to auditory outer hair cell degeneration, the most common cause of hearing loss and neurodegenerative condition in humans. Lysosomes lacking mucolipins undergo organelle membrane permeabilization and promote cytotoxicity with age, revealing a novel mechanism of outer hair cell degeneration and ARHL. These results underscore the importance of lysosomes in hair cell survival and the maintenance of hearing.
Introduction
In the cochlea, sounds are mechanotransduced by hair cells (HCs) of two types, inner HCs (IHCs) and outer HCs (OHCs). While OHCs mechanically amplify sound-induced vibrations of the organ of Corti (Dallos and Fakler, 2002), IHCs signal synaptically to cochlear neurons, communicating auditory information to the brain (Dannhof and Bruns, 1993; Seal et al., 2008). In order for these cells to transduce sounds properly, the stria vascularis maintains a potassium-rich environment in the endolymphatic compartment of the cochlea, which registers a large positive potential (Wangemann, 2006). Damage to sensory, strial, and/or neuronal components can lead to hearing impairment. The most prevalent type of deafness is that acquired with age, termed presbycusis or age-related hearing loss (ARHL), and its most common cause is death of cochlear HCs, particularly of the more vulnerable OHCs (Ohlemiller, 2006; Liberman, 2017). Because mammalian HCs are not generated after an early developmental period, the deafness caused by their loss is irreversible. But for the same reason cochlear HCs must be remarkably resilient, they withstand constant high-energy demands and mechanical stimulations, and yet many survive for the lifetime of the organism, which in humans can amount for over a century. Hence, identification of genes involved in ARHL could lead to elucidating the molecular mechanisms responsible for HC longevity. Despite its prevalence, only a few genes are known to associate with progressive ARHL (Ohlemiller, 2006), probably because the loss is polygenic. One approach to study polygenic ARHL has been to map the multiple loci contributing to hearing loss observed in certain strains of mice (Noben-Trauth et al., 2003; Noguchi et al., 2006; Ohlemiller et al., 2008; Keller et al., 2011). In an alternative approach, we generated double knock-out mice lacking two genes suspected to function in degeneration of cochlear cells but that, when mutated alone, did not cause deafness.
Mucolipins constitute a group of Transient Receptor Potential (TRP) cation channels present in the membranes of lysosomes and late endosomes. In mammals, there are three mucolipins (also known as TRPML1, 2, and 3), encoded by the genes Mcoln1, 2, and 3 (hereby referred to as Trpml1, 2, and 3) (Montell, 2005; Zeevi et al., 2007; García-Añoveros and Wiwatpanit, 2014). Loss-of-function mutations in the human Trpml1 gene cause mucolipidosis Type IV (MLIV), a lipid storage disease resulting in lysosomal overload and cellular degeneration (Schiffmann et al., 1993; Slaugenhaupt, 2002). Trpml1−/− mice appear normal for the first 6–8 months of age, at which time they develop MLIV-like symptoms (motor incoordination, retinal degeneration, and loss of body fat) and die within 2 weeks (Venugopal et al., 2007; Micsenyi et al., 2009). A dominant mutation in the Trpml3 gene causes deafness and vestibular impairment characterized by HC loss, anatomical malformation of the stria vascularis, and reduced endocochlear potential in the Varitint-Waddler (Va) mouse (Cable and Steel, 1998; Di Palma et al., 2002). This gain-of-function mutation resulted in channels with an increased open probability that sustained a constitutive cationic current lethal to cells (Grimm et al., 2007; Kim et al., 2007; Xu et al., 2007; Nagata et al., 2008), which explains the HC death and deafness of the Va mice (Nagata et al., 2008; Castiglioni et al., 2011). However, because the Va mutation results in constitutively active mucolipin 3 channels, it does not reveal the contribution this channel may make to HCs and hearing, which requires a null mutation lacking functional mucolipin 3.
Trpml3−/− mice display no hearing impairment or any other phenotype examined (Jörs et al., 2010; Remis et al., 2014), prompting the suspicion that there are one or more genes with redundant functions. Two obvious candidates are the remaining mucolipins, Trpml1 and Trpml2. Mucolipin 2 is expressed in immune cells and not in most mucolipin 3-expressing cells, including HCs (Montell, 2005; Zeevi et al., 2007; García-Añoveros and Wiwatpanit, 2014). However, mucolipin 1 is ubiquitous (Bach, 2001; LaPlante et al., 2002; Bach et al., 2005) and thus could act redundantly with mucolipin 3, as shown in neonatal enterocytes, which express high levels of both mucolipins 3 and 1 and have specialized giant lysosomes. These cells were severely vacuolated in mice lacking both mucolipins 3 and 1, but not either one alone. This pathology involved an enlargement of the specialized lysosomes characteristic of neonatal enterocytes (Remis et al., 2014). We reasoned that mucolipins 3 and 1 may also act redundantly in the inner ear.
Here, we generated mice lacking mucolipin 3 and mucolipin 1 in HCs. Mice lacking lysosomal mucolipins 3 and 1 in HCs displayed hearing loss progressing from high to low frequencies and with age. Absence of both mucolipins in OHCs caused enlargement and permeabilization of lysosomes, a known source of cellular toxicity, and OHC degeneration. These results represent a novel polygenic form of ARHL that involves two lysosomal channels and a lysosomal mechanism in the degeneration of OHCs with age.
Materials and Methods
Ethics.
All animal care and procedures were in accordance with the Guide for the care and use of laboratory animals published by the National Institutes of Health and were approved by Northwestern University's Institutional Animal Care and Use Committee (Animal Study Protocols: IS00000593, IS00001281, and IS00003625).
Animals.
Wild-type (WT) and Trpml1−/− (ML1KO) mice in this study were littermates generated by mating Trpml1+/− × Trpml1+/−, and had a genetic background of ∼75% C57BL/6 and ∼25% 129S6 (Venugopal et al., 2007). Trpml3−/− (ML3KO) and Trpml3−/−;Trpml1−/− (double knock-out [DKO]) were littermates generated by mating Trpml3−/−;Trpml1+/− × Trpml3−/−;Trpml1+/−, and had a genetic background of ∼75% C57BL/6, ∼12.5% Sv129/Ola, and ∼12.5% 129S6 (Castiglioni et al., 2011; Remis et al., 2014). Finally, mice conditionally lacking mucolipins in HCs only (Gfi1Cre/+;Trpml3F/F;Trpml1−/−, conditional DKO [cDKO]) and their littermate controls (Gfi+/+;Trpml3F/F;Trpml1−/−, Gfi+/+;Trpml3F/F;Trpml1+/+, Gfi+/+;Trpml3F/F;Trpml1+/−, GfiCre/+;Trpml3F/F;Trpml1+/+, GfiCre/+;Trpml3F/+;Trpml1+/+ and GfiCre/+;Trpml3F/+;Trpml1+/−) incorporated Gfi1Cre/+ mice with a mixed background of C57BL/6J and 129S6 (Yang et al., 2010), and had an estimated background of ∼59% C57BL/6, ∼19% Sv129/Ola, and ∼22% 129S6. Hence, all animals used in this study had a similar genetic background of ∼59%-75% C57BL/6 and 41%–25% 129 strains. Importantly, regardless of the slight differences in genetic background, ML1KO mice (littermates of WT) and ML3KO (littermates of DKO) did not differ from WT mice in all aspects examined. Furthermore, cDKO and DKO, although not littermates, had comparable auditory brainstem response (ABR) and distortion product otoacoustic emission (DPOAE) thresholds and virtually identical patterns of HC loss. Hence, the slight differences in genetic background did not result in any auditory phenotype, nor did they alter the hearing and HC loss phenotype segregating with mucolipin codeficiency.
Hearing tests.
During testing, mice of both sexes aged ∼P30 and between P60 and P120 were anesthetized with ketamine/xylazine (100 mg/kg/10 mg/kg, i.p.), and their body temperature was maintained using a heating blanket. Hearing tests were performed on the left ear. DPOAEs were acquired using a custom probe and an in the ear calibration. To determine DPOAE threshold, growth or input–output functions were collected for f2 = 12 kHz and for f2 = 27 kHz (where f2 = 1.2 × f1) with the level of f1 being 10 dB higher than f2. These functions were plotted off line, and the sound pressure level of f1 that produced a cubic difference tone at 2f1-f2 of 0 dB was defined as threshold. ABRs were also acquired to assay auditory nerve activity as well as that in the lower brainstem. For these recordings, subcutaneous needle electrodes were inserted at the vertex and at the mastoid with a reference electrode in the neck region on the opposite side. ABR thresholds were obtained using short tone bursts of decreasing level (step size = 5 dB). Threshold was defined as the level where all ABR waves disappeared into the noise floor. The details of these procedures appear in a previous publication (Cheatham et al., 2014).
Tissue collection and processing.
For neonatal tissues (younger than P14), the animals were killed by decapitation and inner ears dissected in ice-cold PBS. For adult tissues (older than P21), the inner ears were dissected following cardiac perfusion with 2% or 4% PFA after death. Tissues collected from both male and female mice were then postfixed in 2% or 4% PFA for 2 h at room temperature. Adult ears were decalcified either in RDO (Electron Microscopy Sciences) at room temperature for 10 min or in 10% (w/v) EDTA, pH 7.3–7.4, at 4°C for at least 24 h. To prepare frozen sections, the ears were processed and sectioned at 12 μm as described previously (Castiglioni et al., 2011). For whole-mount preparations, the organ of Corti was dissected from the cochlea into one apical, two middle, and one basal segment using a whole-mount surface preparation method described previously (Montgomery and Cox, 2016).
Immunohistochemistry.
Frozen sections were processed as previously described (Castiglioni et al., 2011). The antibodies used for frozen tissue preparation were as follows: TRPML3-CT (1:5000, a gift from Dr. Markus Delling, University of California, San Francisco), lysosomal-associated membrane protein 1 (LAMP1, 1:50, 1D4B-s, Developmental Studies Hybridoma Bank), and KCNQ1 (1:100, sc-20816, Santa Cruz Biotechnology). For TRPML3-CT immunostaining, the sections were subjected to antigen retrieval by incubating in 10 mm sodium citrate, pH 6, with 0.25% Triton X-100 for 20 min at 92°C and cooling for 30 min at room temperature before blocking, and TRPML3-CT immunoreactivity was detected using a SuperBoost tyramide signal amplification kit (B40922, Thermo Fisher Scientific). Whole-mount organ of Corti sections were processed for immunohistochemistry as described previously (Delmaghani et al., 2015). The antibodies used for whole-mount preparation were LAMP1 (1:50), LC3 (1:50, ab58610, Abcam), PMP70 (1:100, ab3421, Abcam), COXIV (1:100, ab16056, Abcam), and Galectin 3 (1:50, ab58802, Abcam). Nuclei were counterstained with DAPI (1:1000, Thermo Fisher Scientific) and stereocilia with the filamentous actin probe phalloidin (1:100, Thermo Fisher Scientific).
Image acquisition.
For immunohistochemistry on frozen sections, we acquired images on either a Leica SP5 confocal or Nikon E600 pan fluorescence microscope equipped with a Nikon DS-Ri2 camera. For whole-mount preparation, we acquired images on either a Nikon A1 confocal, Nikon A1R+ Confocal or Nikon N-structured illumination microscopy structured illumination super-resolution microscope imaging system using a 100× objective. Three-dimensional renderings of confocal images were generated using NIS Elements AR4.60.00 (Nikon) and Imaris X64 8.4.1 (BitPlane) software. Organelle number and volume measurements were performed using built-in analysis functions on Imaris. When comparing controls and mutant immunoreactivities, we captured images with identical settings. After acquisition, we identically processed image pairs of control and knock-out samples. This included adjustment for brightness and contrast.
Cytocochleogram construction.
We used the right cochlea, not previously subjected to hearing tests, for cytocochleogram construction. For each cochlea, all 4 segments from a single whole-mount surface preparation were counterstained for stereocilia. Images were captured at 20×, stitched and reconstructed using either MicroSuite FIVE (Olympus Soft Imaging Solutions) or FIJI (ImageJ). After calculating cochlear length and dividing the cochlea into 7% segments, cytocochleograms were constructed by plotting the average percentage HC loss, determined by the absence of stereocilia staining in each 7% segment along the basilar membrane. Cochlear positions corresponding to 12 and 27 kHz were calculated using a mouse frequency-place map (Müller et al., 2005).
Experimental design and statistical analysis.
For statistical analysis, data were collected from both male and female animals. All statistical tests were performed using Prism software (GraphPad). For consistency, all whole-mount surface preparation measurements were performed on cochlear middle segments, whereas frozen section measurements were on cochlear middle turns of midmodiolar sections. Data are mean ± SEM shown in all plots. Datasets were analyzed for significance using a one-way ANOVA followed by either Tukey's or Dunnett's post hoc tests or unpaired t test based on the n = number of animals, and only one ear per animal was used. The statistical comparison of hearing thresholds in ∼P30 DKO versus adult WT, ML1KO, and ML3KO (see Fig. 1A–D), as well as the comparisons of HC loss in controls (WT, ML1KO, and ML3KO) versus both complete and conditional double knock-out mice (DKO and cDKO) (see Fig. 4F), were unpaired t tests. For all anatomical examinations and immunostainings, we used cochlea from the ears that were not subjected to hearing tests. The number of cells used to collect individual data are shown on the plots. A 95% CI was used to determine significance (p < 0.05). All sample size and p values are reported in the figures or the figure legends.
Results
Mice lacking mucolipins 3 and 1 experience accelerated ARHL
To examine the role of lysosomal mucolipins in auditory function, we tested the hearing of mice lacking mucolipin 1 (ML1KO), lacking mucolipin 3 (ML3KO), and lacking both mucolipins 3 and 1 (DKO), by determining their DPOAE and ABR thresholds at high (27 kHz) and low (12 kHz) frequencies. ABRs measure auditory-evoked neural output from the cochlea to the brainstem (Willott, 2006), whereas DPOAEs reflect OHC function. The latter are measured from the ear canal by presenting a two-tone stimulus (Martin et al., 2006). Adult mice (∼P60-P120) lacking either mucolipin 1 or 3 alone (ML1KO or ML3KO) had comparable ABR and DPOAE thresholds to WT animals at both 27 and 12 kHz (Fig. 1A–D). However, adult DKO mice had significantly higher ABR and DPOAE thresholds than controls (WT, ML1KO, and ML3KO), indicating hearing loss (Fig. 1A,B). The raised ABR and DPOAE thresholds in DKO mice are similar, a characteristic of OHC dysfunction. The ABR threshold shift for DKO mice is greater at high (27 kHz) frequency (61.61 ± 4.57 dB) than at low (12 kHz) frequency (21.57 ± 3.66 dB; Fig. 1A,C). The DPOAE threshold shift is also larger at 27 kHz (at least 43.47 ± 1.40 dB; this is an underestimate because we could not detect thresholds >90 dB) than at 12 kHz (28.28 ± 2.96 dB) (Fig. 1B,D). These data suggest that DKO mice experience hearing loss, which progresses from high to low frequencies, a characteristic of ARHL.
Coabsence of mucolipins 3 and 1 in HCs, but not either alone, causes age-related hearing loss progressing from high to low frequencies. A–H, Hearing thresholds at 27 and 12 kHz determined using ABRs (A, C, E, G) and DPOAEs (B, D, F, H) in adult (∼P60–P120) and juvenile (∼P30) mice. A, B, Adult mice lacking both mucolipins 3 and 1 (DKO), but not either alone (ML1KO or ML3KO), have raised ABR (A) and DPOAE (B) thresholds at 27 kHz compared with WT mice. Juvenile DKO mice (∼P30) exhibit somewhat smaller threshold shifts at 27 kHz for both ABR and DPOAE. C, D, Adult DKO mice have a mild hearing loss at 12 kHz indicated by both ABR (C) and DPOAE (D) threshold shifts. At 12 kHz, juvenile DKO mice have intermediate ABR and DPOAE threshold shifts. E–H, Hearing tests from mice in which mucolipins 3 and 1 are conditionally absent in HCs only (cDKO) indicate that adult cDKO mice (∼P120) have raised hearing thresholds at both 27 (E, F) and 12 (G, H) kHz. Age-matched (P120) data from adult DKO mice from (A–D) were selected and replotted (E–H) to statistically compare the ABR (E, G) and DPOAE (F, H) thresholds between mice lacking mucolipins in all cells versus mice lacking mucolipins in HCs only. *p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001.
Juvenile (P30) DKO mice already exhibit some hearing loss, which, as in the adult, is more pronounced at 27 than at 12 kHz (Fig. 1A–D). ABR threshold shifts of juvenile DKO mice (26.36 ± 3.99 dB at 27 kHz and 9.97 ± 3.82 dB at 12 kHz) are smaller than the threshold shifts of adult DKO mice (61.61 ± 4.57 dB at 27 kHz and 21.57 ± 3.66 dB at 12 kHz) (Fig. 1A,C). Similarly, juvenile DKO mice also exhibit DPOAE threshold shifts (31.15 ± 2.64 dB at 27 kHz and 10.23 ± 3.39 dB at 12 kHz), but the loss of sensitivity is again less than in older adult DKO animals (Fig. 1B,D). Together, our data indicate that mice lacking both mucolipins 3 and 1 suffer an early onset form of ARHL.
Mucolipin 3 and 1 coabsence in HCs causes ARHL
In the cochlea, mucolipin 3 is expressed in both auditory HCs and stria vascularis (Castiglioni et al., 2011) (Fig. 2), whereas mucolipin 1 is ubiquitous (Bach, 2001; LaPlante et al., 2002; Bach et al., 2005). In neonatal cochleae (P11), mucolipin 3 is expressed in IHCs, OHCs, and stria vascularis in a cytoplasmic punctate pattern, consistent with its previously reported lysosomal localization in these cells (Castiglioni et al., 2011). Mucolipin 3 immunoreactivity is primarily located apically in OHCs but dispersed throughout the IHC cytoplasm (Fig. 2A,E). Our results only disagree with this prior report in one aspect: while it was believed that mucolipin 3 disappeared from mature OHCs, we now find that in the mature cochlea (∼P120), OHCs maintain mucolipin 3 immunoreactivity, albeit at a lower level than IHCs (Fig. 2A). In stria vascularis, mucolipin 3 immunoreactivity appears dispersed at P11 but surrounds the nuclei of strial marginal cells by P120 (Fig. 2B,F), as previously reported (Castiglioni et al., 2011). As a negative control and as evidence that the immunoreactivity was specific for TRPML3, immunohistochemistry in ML3KO tissues gave no signal above background in either HCs or stria vascularis (Fig. 2C,D). The restricted expression of mucolipin 3 in HCs and strial cells suggests that mucolipins could contribute to auditory functions of both HCs and stria vascularis.
Mucolipin 3 is localized to HCs and the stria vascularis in both adult and neonatal cochleae. Immunohistochemistry of the mucolipin 3 carboxyl terminus (TRPML3-CT) on adult (∼P120) (A–D) and neonatal (P11) (E–H) cochleae. A, TRPML3-CT labels vesicles in both IHCs and OHCs as well as cells of stria vascularis (B) in WT cochlea. C, D, In ML3KO tissues, there is no TRPML3-CT immunoreactivity detected above the background signals in either HCs (C) or stria vascularis (D). E, F, Neonatal Trpml3F/F HCs express mucolipin 3 in a similar pattern as adult HCs; however, the levels of TRPML3-CT immunoreactivity in P11 OHCs and IHCs are comparable (E). Mucolipin 3 appears more dispersed in the P11 stria vascularis (F). G, H, There is no TRPML3-CT immunoreactivity detected in GfiCre/+;Trpml3F/F HCs (G), although its signal is detected in the stria vascularis (H). Scale bars: A, C, E, G, 10 μm; B, D, F, H, 20 μm. For clarity, HC nuclei and strial boarder were outlined in top panels. SM, Scala media.
Because defects in either HCs (Ohlemiller, 2006; Potter et al., 2016) or in stria vascularis can cause progressive loss of HCs and hearing (Gamp et al., 2003; Knipper et al., 2006; Ohlemiller et al., 2008), accelerated ARHL in DKO mice could be due to the coabsence of both mucolipins 3 and 1 in HCs and/or stria vascularis. To determine which cells require mucolipins 3 and 1 to maintain hearing, we used a floxed allele of Trpml3 (Remis et al., 2014), a complete KO of Trpml1 (Venugopal et al., 2007), and the HC-specific Gfi1Cre line (Yang et al., 2010) to generate mice conditionally lacking both mucolipins 3 and 1 in HCs but not in strial cells (cDKO). In the cochlea of these mice, GfiCre ablates Trpml3 only in auditory HCs (Fig. 2E–H), whereas all cells lack mucolipin 1. Because animals lacking either mucolipin 1 or 3 alone do not experience hearing defects (Fig. 1A–D), we grouped together littermate controls for statistical analysis.
We found that adult (∼P120) cDKO mice experienced hearing loss like DKO mice with comparable auditory threshold shifts and frequency dependence (Fig. 1). Specifically, ABR threshold shifts among adult cDKO were 45.30 ± 10.31 dB at 27 kHz and 14.32 ± 6.51 dB at 12 kHz (Fig. 1E,G). DPOAE threshold shifts for adult cDKO were 30.12 ± 5.91 dB at 27 kHz and 27.23 ± 5.12 dB at 12 kHz (Fig. 1F,H). ABR and DPOAE threshold shifts were again more severe at high (27 kHz, Fig. 1E,F) than low (12 kHz, Fig. 1G,H) frequencies, the same pattern observed in adult DKO mice (Fig. 1A–D). Finally, ABR and DPOAE thresholds for ∼P120 cDKO mice did not differ from those observed in ∼P120 DKO mice (Fig. 1E–H). Hence, we concluded that coabsence of mucolipins 3 and 1 in HCs was the cause of the early-onset ARHL observed in our mouse models.
Lysosomal defects in stria vascularis can lead to progressive hearing loss. In particular, in mice mutant for lysosomal LIMP2, the potassium channel KCNQ1 is not localized to the apical membrane of strial marginal cells, and this leads to progressive hearing loss and HC degeneration (Gamp et al., 2003; Knipper et al., 2006). Hence, we examined the stria vascularis of mucolipin-codeficient adult (4- to 4.5-month-old) mice. The stria vascularis was of normal thickness, and KCNQ1 was properly localized in DKO mice (Fig. 3A,B). The lack of an anatomical phenotype is consistent with the genetic evidence that mucolipins are required in HCs, but not in strial cells, to prevent early-onset ARHL.
There is an anatomical defect in OHCs but not in the stria vascularis from cochleae lacking both mucolipin 3 and 1. A, Immunoreactivity of potassium channel KCNQ1 in the stria vascularis shows that there is no mislocalization of this channel in DKO cochlea compared with WT, ML1KO, and ML3KO animals. SM, Scala media. B, Quantification of strial thickness indicates that there is no strial degeneration in DKO cochlea. C, D, Actin labeling reveals that OHCs (C), but not IHCs (D), from DKO cochlea are larger than those of control cochleae. E, F, Quantification of HC apical surface area, measured just under the cuticular plate of HCs from middle turn, confirms that DKO OHCs are larger than the controls. Samples were from 4- to 4.5-month-old animals. Scale bars: A, 20 μm; C, D, 5 μm. ****p ≤ 0.0001.
On the other hand, we observed a small but consistent increase in OHC (∼1.4-fold), but not IHC size, in DKO cochleae, determined by the surface area of HCs just under the cuticular plate (Fig. 3C–F). This could be an early sign of OHC dysfunction leading to hearing loss in mice lacking mucolipins 3 and 1 in HCs as cells in the process of dying are often swollen (Trump et al., 1997). These results further suggest that the lack of mucolipins 3 and 1 in HCs, especially OHCs, is likely the primary cause of early-onset ARHL in these mice.
Mucolipin 3 and 1 coabsence in HCs causes OHC degeneration
The most common cause of deafness and hearing loss is degeneration of OHCs. Hence, we examined the cochleae of adult (∼P120) mice subjected to hearing testing. At the cochlear positions associated with 27 and 12 kHz (Müller et al., 2005), there is no IHC loss regardless of genotype (Fig. 4A). However, there is a high degree of OHC loss in DKO and cDKO cochleae, especially at the basal 27 kHz place, but not in WT, ML1KO, and ML3KO controls (Fig. 4A–E). The level of OHC loss at the ∼27 kHz position is much greater than that at ∼12 kHz, which is consistent with the greater ABR and DPOAE threshold shifts at 27 kHz (Fig. 1). Cytocochleograms also reveal that WT, ML1KO, and ML3KO mice display a loss of OHCs at the extreme base of the cochlea (Fig. 4F). This loss, accompanied by high-frequency hearing loss, is a characteristic of the C57BL/6 inbred strain (Parham, 1997; Spongr et al., 1997; Ison et al., 2007). Because all mice tested have a genetic background of C57BL/6 mixed with Sv129 and 129S6, and the ABR and DPOAE thresholds of the ML1KO and ML3KO mice do not differ from those of their WT littermates (Fig. 1A–D), their loss of OHCs at the extreme base is not attributed to the loss of mucolipins. However, the cytocochleograms of DKO and cDKO mice reveal a much greater OHC loss at more apical positions compared with littermate controls. In addition, the fact that there is no obvious IHC loss in DKO and cDKO mice agrees with their comparably raised DPOAE and ABR thresholds, which are characteristic of OHC dysfunction (Fig. 1B–H). This pattern of OHC loss, from high (cochlear base) to low (cochlear apex) frequencies, is consistent with the pattern of hearing loss observed (Fig. 1). Finally, the extent of OHC loss was virtually identical between DKO and cDKO mice, which demonstrates that the cause of OHC degeneration is the coabsence of mucolipins 3 and 1 in HCs, and not in strial cells (Fig. 4F).
Age-related hearing loss in animals lacking both mucolipin 3 and 1 is accompanied by OHC death. A–E, Actin labeling shows HCs from a whole-mount surface preparation of the adult cochlea (∼P120). Cochlear positions transmitting sound at 12 and 27 kHz were calculated using a mouse frequency-place map (Müller et al., 2005). There is no HC loss at 12 and 27 kHz positions in WT (A), ML1KO (B), and ML3KO (C) cochleae. However, OHC loss can be observed in DKO (D) and cDKO (E) cochleae (asterisks). The extent of OHC loss is more severe at the 27 kHz position. No IHC loss was observed at either position. F, Cytocochleograms showing %OHC and %IHC loss along the cochlear spiral for all genotypes (A–E). *p = 0.014. **p = 0.009. ***p = 0.0008. ****p ≤ 0.0001. Arrowheads indicate positions corresponding to 12 and 27 kHz. Scale bars, 10 μm.
Lysosomes in OHCs lacking mucolipins 3 and 1 are enlarged
Because mucolipins are lysosomal channels, we examined these organelles using immunohistochemistry for the lysosomal marker LAMP1. First, we found that DKO OHCs have enhanced LAMP1 immunoreactivity compared with control OHCs (Fig. 5A,B). When comparing whole-cell LAMP1 fluorescence from immunohistochemistry on frozen cochlear sections, DKO OHCs have ∼3.7-fold higher LAMP1 immunoreactivity than those from control cochleae (Fig. 5C: WT, 6656 ± 2561 arbitrary units of fluorescent intensity [AU]; ML1KO, 5730 ± 2166 AU; ML3KO, 7721 ± 2063 AU; DKO, 30,793 ± 6917 AU). This lysosomal enrichment in DKO OHCs was not dependent on their position along the length of the cochlea, as we did not observe differences in LAMP1 staining in OHCs from middle, apical-middle, or apical turns (Fig. 5D). Hence, to further explore the subcellular basis of ARHL in DKO mice, we consistently examined OHCs from middle cochlear turns, which approximately correspond to 25%–75% distance from the cochlear apex, and hence to the area of OHC loss (Fig. 4F).
OHCs lacking mucolipins 3 and 1 possess pathologically enlarged lysosomes. A, Immunoreactivity of LAMP1 (a lysosomal membrane protein) in adult (∼P120) OHCs reveals apical accumulation of lysosomes in DKO OHCs but not in those from WT, ML1KO, and ML3KO control cochleae. B, Super-resolution structured illumination microscopy shows that DKO OHCs, but not the controls, possess enlarged lysosomes as indicated by LAMP1 immunoreactivity. B, Images were OHCs from row 2. C, Quantification of total whole-cell LAMP1 fluorescence from A reveals a significant increase in LAMP1 in DKO OHCs but not in control cochleae. D, LAMP1 whole-cell intensity values used in C are replotted separately based on cochlear position (apical, apical/middle, and middle). We observed no difference in OHC LAMP1 intensity between cochlear turns within each genotype. E, LAMP1 intensity values used in C are replotted, binning the apical-basal axis of OHCs in three segments based on the percentage distance from the nucleus. F, By measuring LAMP1 vesicle diameter from images taken from confocal and structured illumination microscopy, we found that lysosomal diameter of DKO OHCs is ∼2.18-fold larger than that from control OHCs. G, A frequency distribution plot of LAMP1 vesicle diameter in all genotypes. Scale bars: A, 5 μm; B, 2 μm. *p < 0.05; **p < 0.01; ***p < 0.001; ****p ≤ 0.0001.
The lysosomal (LAMP1) increase in DKO OHCs was not homogeneous throughout the cells but concentrated at their most apical third. At the basal third (0%–33% distance from the nucleus) of the cell, DKO OHC contained approximately the same amount of LAMP1 immunofluorescence as control OHCs (Fig. 5E: WT, 3086 ± 1174 AU; ML1KO, 2202 ± 887 AU; ML3KO, 2268 ± 554 AU; DKO, 3560 ± 851 AU). There was a slight increase in overall LAMP1 at the middle third (34%–66% distance from the nucleus) of DKO OHC (Fig. 5E: WT, 943 ± 384 AU; ML1KO, 845 ± 278 AU; ML3KO, 1381 ± 509 AU; DKO, 4094 ± 1019 AU). However, there was a striking increase of LAMP1 fluorescence at the apical third portion of DKO OHCs (Fig. 5E: WT, 2621 ± 1087 AU; ML1KO, 2683 ± 1070 AU; ML3KO, 4119 ± 1143 AU; DKO, 23,139 ± 5397 AU).
The increase on LAMP1 immunoreactivity could be due to an increase in LAMP1 protein concentration in lysosome membranes, in the number of lysosomes, or in their size. To more accurately visualize lysosomes in OHCs, we performed LAMP1 immunohistochemistry on whole-mount surface preparations of the organ of Corti (which affords better preservation of cellular structures that frozen sections) and imaged them with super-resolution structured illumination microscopy. Because LAMP1 localizes to the membrane of lysosomes, we used its immunofluorescence to measure lysosomal size. To facilitate comparisons, we used the same criteria for selection of representative lysosomes for measurements in control and DKO OHCs: (1) we only selected lysosomes that were visibly isolated as the microscope could not resolve objects closer than ∼100 nm; and (2) we only measured lysosomal diameter using the optical plane that yielded the largest diameter because we found lysosomes to be approximately spherical. Our examinations indicate that lysosomes (LAMP1-positive vesicles) were larger in OHCs from DKO cochleae than those from the controls (Fig. 5B). Specifically, lysosomes from DKO OHCs had a 2.18-fold larger diameter than those measured from control OHCs (Fig. 5B,F: WT, 0.257 ± 0.01 μm; ML1KO, 0.243 ± 0.003 μm; ML3KO, 0.322 ± 0.04 μm; DKO, 0.560 ± 0.02 μm). Increasing lysosomal diameter by 2.18-fold (from WT to DKO) would result in a 4.75-fold increase in lysosomal surface area, which accounts for the 4.63-fold increase in LAMP1 immunoreactivity, as it is a lysosomal membrane marker (Fig. 5C). Moreover, we found that DKO OHCs not only have larger lysosomes (∼0.25–0.8 μm) but also fewer smaller ones (∼0.15–0.4 μm), of the size typically found in control OHCs (Fig. 5G). Our results suggest that the increase in overall LAMP1 fluorescence observed in mucolipin-codeficient OHCs (Fig. 5A,C) is not due to an increase in the number of lysosomes or in the density of LAMP1 protein, but to an increase in the size of the lysosomes.
Autophagy, mitophagy, and pexophagy appear unaltered in mucolipin-codeficient OHCs
Lysosomal defects have been shown to lead to cytotoxicity in two ways. One is by a failing to degrade damaged organelles (e.g., mitochondria or peroxisomes) that have become toxic, a process generally performed through autophagy (Raben et al., 2009; Jegga et al., 2011; Button et al., 2017). Another way lysosomes can harm cells is by becoming toxic themselves, a process involving permeabilization of their membranes (Boya and Kroemer, 2008; Oku et al., 2017). Lysosomes harbor within their lumens hydrolytic enzymes that would be harmful if released into the cytosol. We explored whether either of these mechanisms could account for the OHC degeneration caused by mucolipin codeficiency. Initially, we focused on organelles whose dysfunction causes OHC loss: peroxisomes (Delmaghani et al., 2015) and mitochondria (Chen and Tang, 2014; Seo et al., 2017). These organelles have a limited lifespan and, when damaged, are removed by lysosomes through the processes of pexophagy and mytophagy. If these processes were impaired, we would expect an increase in the number of such organelles.
Because dysfunctional and/or damaged peroxisomes can increase sensitivity to noise-induced hearing loss, even at neonatal stages (Delmaghani et al., 2015), we used a peroxisomal marker PMP70 to examine whether there was any peroxisomal accumulation or defect in DKO OHCs (Fig. 6A,D,E). Both control and DKO OHCs had similar numbers of peroxisomes per cell (Fig. 6D: WT, 5.32 ± 0.42; ML1KO, 4.73 ± 0.45; ML3KO, 6.16 ± 0.64; DKO, 5.26 ± 0.73), and the peroxisomes were of similar size (Fig. 6E: WT, 0.289 ± 0.024 μm3; ML1KO, 0.225 ± 0.015 μm3; ML3KO, 0.282 ± 0.040 μm3; DKO, 0.204 ± 0.01 μm3). Hence, we did not detect peroxisomal abnormalities in mucolipin-codeficient OHCs.
Enlarged lysosomes in OHCs lacking mucolipin 3 and 1 do not cause defects in lysosomal degradation of damaged organelles. A–C, Whole-mount cochleae from WT, ML1KO, ML3KO, and DKO adult (∼P120) animals using different organelle markers: peroxisome (PMP70, A), mitochondria (COXIV, B), and autophagosome (LC3, C). There is no apparent defect in distributions and numbers of peroxisomes (A), mitochondria (B), and autophagosomes (C). Representative images were reconstructed from a projection of 8 confocal optical sections spanning 0.88 μm under the cuticular plate. D, E, The number of peroxisomes per OHC and peroxisomal volume, indicated by PMP70 immunoreactivity, from DKO OHCs are similar to those from controls. F, Whole-cell fluorescence of COXIV did not differ between DKO and control OHCs. G, H, The number of autophagosomes per OHC and autophagosomal volume, indicated by LC3 immunoreactivity, from DKO OHCs are similar to controls. Scale bars, 5 μm.
Because defects in mitochondrial physiology can cause HC death (Fischel-Ghodsian et al., 1997; Chen and Tang, 2014), we examined whether there was any mitochondrial defect in DKO OHCs using antibodies to the mitochondrial cytochrome C oxidase subunit IV (COXIV) (Fig. 6B). COXIV immunoreactivity was strong and dense along the OHC's basolateral membrane and under the apical cuticular plate (Fig. 6B). Because mitochondria exist in a range of shapes and sizes from tubular to fragmented (Westermann, 2012), our confocal imaging could not quantify the number of these organelles. We therefore examined whole-cell intensity of COXIV immunoreactivity in individual OHCs as an indirect way to determine whether there was mitochondrial accumulation. Similar to the PMP70 immunostaining, we did not detect any difference in COXIV whole-cell fluorescence in DKO OHCs compared with controls (Fig. 6F: WT, 170,385 ± 5483 AU; ML1KO, 162,342 ± 19,183 AU; ML3KO, 192,623 ± 44,740 AU; DKO, 178,165 ± 34,829 AU).
Lysosomes degrade these and other damaged organelles via autophagy, a process in which a double membrane encircles the cellular components to be degraded, forming an autophagosome that fuses with the lysosome. Because defects in autophagy have also been found to promote ARHL and HC degeneration (Fujimoto et al., 2017), we used immunoreactivity to LC3 to visualize autophagosomes. Although LC3 exists in a diffuse cytosolic form, it will coalesce on autophagosome membranes, giving a punctate pattern (Mizushima, 2009). We found that there was no increase or decrease in autophagosomes in DKO OHCs as indicated by the number of LC3 puncta (Fig. 6C,G,H). Specifically, both control and DKO OHCs have ∼14 autophagosomes per cell (Fig. 6G: WT, 13.98 ± 1.85; ML1KO, 15.73 ± 0.78; ML3KO, 15.22 ± 1.32; DKO, 13.50 ± 1.16). We also noted no alteration in the volume of autophagosomes, which is ∼0.1 μm3 (Fig. 6H: WT, 0.104 ± 0.030 μm3; ML1KO, 0.098 ± 0.031 μm3; ML3KO, 0.141 ± 0.014 μm3; DKO, 0.103 ± 0.030 μm3).
In conclusion, we detected no aberrant accumulation (or decrease) of autophagosomes, peroxisomes, or mitochondria in OHC lacking mucolipins 3 and 1, as would be expected if lysosomes failed to perform the intracellular digestion of damaged organelles.
Lysosomes in OHCs lacking mucolipins 3 and 1 are permeabilized
Lysosomal membrane permeabilization can trigger multiple cell death pathways, presumably due to the release into the cytosol of the hydrolytic enzymes normally safely retained within the lumen of the organelle (Brunk et al., 1997; Ono et al., 2003; Boya and Kroemer, 2008; Aits et al., 2015). Because larger lysosomes are more susceptible to lysosomal membrane permeabilization (Ono et al., 2003), we examined lysosomal integrity in OHCs using the galectin 3 assay as an indicator of lysosomal membrane permeabilization (Aits et al., 2015). Galectin 3 is a cytosolic lectin with high binding affinity to the glycocalyx located on the luminal surface of lysosomes. Because galectin 3 is impermeable to membranes, it does not normally localize to the lumen of lysosomes. However, if the lysosomal membrane is compromised, galectin 3 translocates to the lumen. Indeed, we observed puncta of galectin 3 immunoreactivity in DKO OHCs associated with lysosomes, as indicated by a double-staining of LAMP1 and galectin 3 (Fig. 7D), whereas the galectin 3 signal in control OHCs was cytosolic (Fig. 7A–C). In addition, super-resolution structured illumination microscopy reveals that galectin 3 is surrounded by the lysosomal membrane marker LAMP1 and, therefore, localized to the lysosomal lumen (Fig. 7E).
OHCs lacking mucolipin 3 and 1 exhibit lysosomal membrane permeabilization. A–D, Immunoreactivity of galectin 3, a membrane-impermeable cytosolic lectin with high affinity for the luminal lysosomal glycocalyx (Aits et al., 2015), and LAMP1 reveal that lysosomal membranes in DKO OHCs are permeabilized. Galectin 3 is cytosolic in WT (A), ML1KO (B), and ML3KO (C) OHCs, and its expression level varied. D, In contrast, galectin 3 immunoreactivity has a vesicular pattern that is associated with LAMP1 signal in DKO OHCs. E, Super-resolution–structured illumination microscopy shows that galectin 3 is localized to lysosomal lumen. F–I, Immunoreactivity of cathepsin D and LAMP1 reveals that, upon lysosomal permeabilization, DKO lysosomes contain very low levels of cathepsin D. Cathepsin D has a vesicular expression pattern strongly associated with lysosomes in WT (F), ML1KO (G), and ML3KO (H) OHCs. I, In contrast, cathepsin D levels are low or undetectable in DKO lysosomes. Samples were from adult (∼P120) animals. Scale bars: A–D, F–I, 5 μm; E, 2 μm.
An expected consequence of lysosomal membrane permeabilization would be the release of hydrolytic enzymes from the lysosomal lumen to the cytosol. In the controls, cathepsin D is localized to the lysosomal lumen, as indicated by its association with LAMP1 immunoreactivity (Fig. 7F–H). Conversely, in DKO OHCs, most of the enlarged lysosomes contain undetectable to low levels of cathepsin D (Fig. 7I). The absence of cathepsin D in DKO lysosomes is consistent with the presence of galectin 3 in the lysosomal lumen, confirming that the lysosomal membrane is permeabilized in DKO. Although we could not detect cathepsin in the cytosol of DKO OHCs, we reason that its vastly larger volume dilutes cathepsin D below the level of detection. Altogether, mucolipin-codeficient lysosomes have permeabilized membranes, a condition known to cause the release of toxic hydrolases into the cytosol (Boya and Kroemer, 2008; Li et al., 2016; Oku et al., 2017).
Discussion
Although lysosomal defects have been noted to cause hearing loss (Ohlemiller et al., 2002; Heldermon et al., 2007; Schachern et al., 2007), our findings implicate HC lysosomes for the first time in ARHL and HC degeneration. In the case of mucopolysaccharidosis I (Schachern et al., 2007) and mucopolysaccharidosis IIIB (Heldermon et al., 2007), deafness includes loss of both HCs and supporting cells of the organ of Corti. However, because lysosomal vacuolation was not detected in HCs but was found prominently in supporting cells, defective HC lysosomes were not considered the cause of HC degeneration and deafness. These studies, however, did not selectively ablate lysosomal genes in HCs, as we did here to reveal that the source of HC loss was cell autonomous and not due to defects in supporting cells.
The genetic and subcellular bases of ARHL have proven arduous to uncover (Ohlemiller, 2006; Liberman, 2017). By using transgenic mouse models with codeficiency of lysosomal mucolipins 3 and 1 in HCs, we found a novel, polygenic cause for early-onset ARHL accompanied by OHC loss. Our findings implicate two new genes, Trpml1 and Trpml3, adding to the exiguous list of genes that participate in the complex pathologies associated with presbycusis. This hearing loss phenotype is polygenic because of the redundancy between Trpml1 and Trpml3. It is unclear why HCs would require both mucolipins to maintain their longevity because there is no hearing phenotype or HC degeneration in mice lacking either mucolipin alone (Jörs et al., 2010). However, this redundancy also occurs in neonatal intestinal enterocytes where a pathology was observed in DKO mice, but not in ML1KO and ML3KO mice (Remis et al., 2014). As with other cases of genetic redundancy, it is possible that mucolipin 3 serves a subtle lysosomal function that we can only detect in the absence of mucolipin 1. Nonetheless, and although we did not detect any enhanced ARHL even in aged (8-month-old) ML3KO mice (data not shown), we should not rule out the possibility that in the much longer lifespan of decades mucolipin 3 deficiency might predispose humans to an earlier onset ARHL.
While mucolipin 1 is expressed in lysosomes of all cell types (Bach, 2001; LaPlante et al., 2002; Bach et al., 2005), mucolipin 3 is expressed in only a small subset of cells (Nagata et al., 2008; Remis et al., 2014). This restricted expression suggests that cells expressing mucolipin 3 may have specialized lysosomes. Indeed, mucolipin 3-expressing neonatal intestinal enterocytes have giant lysosomes dedicated to the intracellular digestion of endocytosed proteins from maternal milk (Remis et al., 2014). Mucolipin 3-expressing melanocytes produce melanosomes from specialized premelanosomal lysosomes (Raposo and Marks, 2002; Schiaffino, 2010); and marginal cells of the stria vascularis, which also express mucolipin 3 (Nagata et al., 2008), use lysosomes to localize potassium KCNQ1 channels to their apical membranes (Knipper et al., 2006). Hence, it seems reasonable to hypothesize that HCs, expressing mucolipin 3, may also have specialized lysosomes.
Our original hypothesis was that HCs have specialized lysosomes for self-repair and maintenance, and hence for their ability to survive in a challenging environment for a very long time (in many cases for as long as the lifetime of the organism). Although the loss of OHCs due to mucolipin codeficiency favored this hypothesis, we found no evidence that in these OHCs the lysosome-mediated repair mechanisms (autophagy, mitophagy, and pexophagy) are compromised (Fig. 6). Although the hypothesis that HCs contain specialized lysosomes dedicated to a self-repair required for their remarkable longevity is still valid, this is not the reason for OHC loss due to mucolipin codeficiency. Instead, we reveal another mechanism by which OHC vulnerability may be increased: swelling and permeabilization of lysosomes, which would lead to the release of lysosomal hydrolases into the cytosol (Fig. 7). Studies have shown that lysosomal enlargement is a common event preceding cell death, and that enlarged lysosomes are vulnerable to lysosomal membrane permeabilization (Ono et al., 2001, 2003). Lysosomal membrane permeabilization causes leakage of luminal contents into the cytosol, including the smaller of the ∼50 types of hydrolytic enzymes (Schröder et al., 2010), which can trigger cell death through apoptosis or necrosis (Boya and Kroemer, 2008; Repnik et al., 2014; Li et al., 2016). Accordingly, we noted a depletion of cathepsin D, one of the smaller hydrolases, from mucolipin-codeficient lysosomes (Fig. 7I). This depletion of cathepsin D does not seem to impair the overall function of the lysosomes (at least in regards to pexophagy, mitophagy, and autophagy; Fig. 6), presumably because they retain most of their (larger) hydrolases (Schröder et al., 2010; Repnik et al., 2014).
Causes of lysosomal membrane permeabilization include osmotic lysis and direct membrane lysis by surfactant activity (Repnik et al., 2014). In our case, lysosomal membrane permeabilization might be due to increased luminal osmotic pressure, as lysosomes lacking mucolipin 3 and 1 are abnormally large (Fig. 5).
It is also of interest that lysosomal membrane permeabilization in OHCs lacking mucolipins is not immediately cytotoxic. OHCs survive with permeabilized lysosomes for weeks to months but in time perish along a base to apical gradient characteristic of OHC loss during ARHL. Hence, the toxic effects of lysosomal enlargement and permeabilization are to enhance the vulnerability of OHCs, whose degeneration ultimately depends on other factors related to age and position. The weak toxicity resulting from lysosomal permeabilization may be due to the pH dependence of lysosomal hydrolases, as they function best at the low pH of the lysosomal lumen and are much less active at cytosolic pH levels. While most lysosomal hydrolases are inactive at a neutral pH, a family of lysosomal hydrolases, notably cathepsins D, L, and S, is known to be active in the cytosol (Lkhider et al., 2004; Vasiljeva et al., 2005; Jiang et al., 2006; Boya and Kroemer, 2008). While cathepsins eventually unfold, losing their hydrolytic properties, their preserved activities, even only for a matter of hours, is sufficient to induce cell death signaling (Turk et al., 2012). Because cathepsin represents a small subset of lysosomal enzymes (Schröder et al., 2010) and lysosomal content accounts for a small portion of total cytoplasmic volume, these lysosomal enzymes would be diluted in the cytosol of OHCs, rendering their hydrolytic activities gradual and cumulative, thereby leading to progressive OHC denegation in ARHL.
Mucolipins have been implicated in multiple aspects of lysosomal function. For example, both mucolipins 3 and 1 facilitate scission of the endolysosomal hybrid organelles in neonatal intestinal enterocytes (Remis et al., 2014), whereas mucolipin 1 facilitates lysosomal fusion to endosomes in macrophages (Thompson et al., 2007). Studies reported that mucolipins function in lysosomal exocytosis in different cell types. For instance, in a bladder epithelial cell line, mucolipin 3 facilitates lysosomal exocytosis for pathogen expulsion (Miao et al., 2015), whereas mucolipin 1 regulates lysosomal exocytosis as a part of plasma membrane repair in muscle fibers (Cheng et al., 2014). Here we report a novel role of mucolipins that affects lysosomal volume and lysosomal membrane integrity. Although we can only speculate as to the molecular steps leading to these organelle defects, one possibility is an increased lysosomal osmotic pressure due to cation accumulation. Because both mucolipin 3 and 1 are inwardly rectifying lysosomal cation channels, their absence would prevent cations from leaving the lysosome. Upon accumulation of luminal cations, the osmotic pressure would increase, ultimately leading to lysosomal membrane destabilization and permeabilization.
In conclusion, we identify a new mechanism by which toxic organelles, in our case lysosomes lacking mucolipin 3 and 1, could lead to premature OHC death and ARHL. We also demonstrate a novel role of mucolipin channels in sustaining lysosomal size and lysosomal membrane integrity. The discovery that mice lacking both lysosomal mucolipins 3 and 1 display accelerated ARHL due to OHC degeneration underscores the importance of lysosomes in long-term HC survival.
Footnotes
This work was supported by National Institutes of Health Grants R01 HD086719 and R01 DC015903 to J.G.-A. and Grant DC000089 to M.A.C. The genetically engineered mice were generated with the assistance of the Transgenic and Targeted Mutagenesis Laboratory, supported in part by National Institutes of Health Grant CA60553 to the Robert H. Lurie Comprehensive Cancer Center at Northwestern University. Imaging work was performed at the Northwestern University Center for Advanced Microscopy supported by National Cancer Institute Grant CCSG P30 CA060553 to the Robert H. Lurie Comprehensive Cancer Center.
The authors declare no competing financial interests.
- Correspondence should be addressed to Dr. Jaime García-Añoveros, Northwestern University, 303 East Chicago Avenue, Ward10-070, Chicago, IL 60611. anoveros{at}northwestern.edu
References
In this issue
